Please assess the completion status of the following clinical trial:

Trial Title: Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~* Documented diagnosis of Relapsing Multiple Sclerosis (McDonald 2010 Criteria ).~* \<3 year disease duration.~* Must have an Expanded Disability Status Scale (EDSS) score from 0 to 4.0, inclusive.~* Anti-JCV antibody negative test within 6 months of Screening Visit.~* Must satisfy the approved therapeutic indications for Tysabri.~* Must be treatment-naïve to disease-modifying therapy (DMT) or have been treated with DMT (including but not limited to Avonex, Betaseron, Rebif, Copaxone, Extavia, or Gilenya) for ≤36 months total prior to date of informed consent.~* Decision to treat with Tysabri must precede enrollment.~Key Exclusion Criteria:~* Any prior treatment with Tysabri.~* Anti-JCV antibody positive at any timepoint prior to the Screening Visit.~* Contraindications to treatment with Tysabri as described in the US Prescribing Information.~* History of progressive multifocal leukoencephalopathy (PML) or other opportunistic infections, or an increased risk for such infections.~* History of diagnosis of Primary Progressive Multiple Sclerosis (PPM) and/or Secondary Progressive Multiple Sclerosis (SPMS).~* Receiving immunomodulatory or immunosuppressive therapy.~* Prior history of immunosuppressive use (mitoxantrone, azathioprine, methotrexate, cyclophosphamide, mycophenolate, cladribine, rituximab).~* Immunocompromised at the time of enrollment.~* Known active malignancies (subjects with cutaneous basal cell carcinoma that has been completely excised prior to study entry remain eligible).~* Women breastfeeding, pregnant, or planning to become pregnant; women who are not post-menopausal or surgically sterile who are unwilling to practice contraception.~* Inability to comply with study requirements.~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).